



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/826,069	04/04/2001	Yaakov Naparstek	56040-B/JPW/GJG/CSN	3884

7590 12/20/2004

Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, NY 10036

EXAMINER

EWOLDT, GERALD R

ART UNIT	PAPER NUMBER
----------	--------------

1644

DATE MAILED: 12/20/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

### Application No.

09/826,069

### Applicant(s)

NAPARSTEK, YAAKOV

### Examiner

G. R. Ewoldt, Ph.D.

### Art Unit

1644

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 08 October 2004.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 8-10 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 8-10 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |   |   |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                        | 4) <input type="checkbox"/> Interview Summary (PTO-413)                     |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)    | Paper No(s)/Mail Date. _____  |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| Paper No(s)/Mail Date _____   | 6) <input type="checkbox"/> Other: _____                                    |

### DETAILED ACTION

1. Applicant's amendment and remarks, filed 10/08/04, are acknowledged. In view of Applicant's amendment, in particular, the deletion from the claims of the term "lupus antibodies", the previous rejections under the first and second paragraphs of 35 U.S.C. 112 have been withdrawn.
2. Claims 1-7 have been canceled.  
Claim 8 and newly added Claims 9 and 10 are being acted upon.
3. Claim 8 is objected to. The "™" symbol after "Sepharose" has been deleted.
4. As set forth previously, the priority date of the instant application is its filing date, 4/04/2001.
5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:  
(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
6. Claim 8 and newly added Claims 9 and 10 stand/are rejected under 35 U.S.C. 103(a) as being unpatentable over Gaubitz, M., et al. (1999) in view of U.S. Patent No. 6,228,363 (priority date 3/20/1998) and Madaio, M., et al. (1996).

As set forth previously,

Gaubitz, M., et al. teaches a method of treating lupus comprising extracorporeal column immunoadsorption of a subject's plasma for the removal of pathogenic antibodies. The reference further teaches that dsDNA-Ab play a "pivotal" role in the pathogenesis of SLE and that their removal proved useful for the treatment of the disease (see particularly Introduction and Discussion).

The reference teaching differs from the claimed invention only in that it does not teach a method employing a column comprising the R38 peptide nor the use of a Sepharose™ column.

The '363 patent teaches that the R38 peptide is derived from laminin and is recognized by pathogenic lupus antibodies (see particularly column 3, lines 13-19).

Madaio et al. teaches that dsDNA-Ab from lupus patients also recognize laminin (see particularly Abstract).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to perform a method of treating lupus comprising extracorporeal column immunoadsorption of a subject's plasma for the removal of pathogenic antibodies, as taught by Gaubitz et al., employing the R38 peptide of the '363 patent. One of ordinary skill in the art at the time the invention was made would have been motivated to employ the R38 peptide on an immunoadsorption column given the teachings of Madaio et al. that dsDNA-Ab from lupus patients also recognize laminin and the '363 patent that the R38 peptide is derived from laminin and is recognized by pathogenic lupus antibodies. Note that Claim 8 is included in the rejection because various types of immunoadsorber matrices (including Sepharose™) for column chromatography were well-known in the art at the time of the invention. The choice of any particular immunoadsorber matrix would have comprised only routine optimization of the claimed method and would have been well within the purview of one of ordinary skill in the art at the time of the invention. Note that new claim 10 does not recite any new limitations because all ligands are coupled to Sepharose™ in some sort of "coupling buffer" (an ordinarily skilled artisan would know that Sepharose™ could not be used in a dry form for column chromatography because column chromatography employs the flow of liquid through the column).

Applicant's arguments, filed 10/08/04, have been fully considered but they are not persuasive. Applicant argues a lack of motivation to combine the references and a lack of expectation of success. Applicant argues that the '363 patent does not teach the attachment of R38 peptides to chromatographic beads nor that the R38 peptides could be used to treat SLE.

Had the reference taught the attachment of R38 peptides to chromatographic beads it would likely have comprised 102 art. The reference clearly teaches that the R38 peptide binds "pathogenic lupus antibodies" and that the peptides have "therapeutic potential" by binding lupus antibodies.

Applicant argues that the Gaubitz et al. and Madaio et al. references provide no suggestion nor motivation to try other

immunoabsorbent agents and further argues that the references indicate that changes to the system cannot be predicted.

A review of the references reveals that various methods of immunoabsorption had been known for years. See, for example, Gaubitz et al. Table 1, which teaches four different immunoabsorbents acting through four different mechanisms, all used in the treatment of SLE. The authors tested a method of immunoabsorption employing two disparate immunoabsorbers; both proved effective in lowering pathogenic antibodies and disease activity. In view of these results, sound scientific reasoning would lead to the conclusion that a method of immunoabsorption employing an immunoabsorber known to bind pathogenic lupus antibodies (such as R38) would have a reasonable expectation of success. Applicant's lack of expectation of success argument seems curious in view of the fact that the specification provides no demonstration that the claimed method would be effective; indeed the claimed method's enablement must rely on the teachings of the prior art. The specification discloses no more than the fact that R38 binds an antibody found in an SLE patient's plasma (Example 12). Applicant is also again reminded of the teachings of the inventor himself as set forth above, i.e., that the ability of the R38 peptide to bind pathogenic lupus antibodies can be exploited for the treatment of SLE.

Applicant argues unpredictable results in removing 30-60% of the pathogenic antibodies from the plasma of an SLE patient (Example 12).

A review of the Example shows that just a tiny 5 ml column was employed that could hardly be considered predictive of what would, or would not, be unpredictable on the scale of the claimed method. Regardless, in the experiments of Gaubitz et al., on a more realistic scale, up to 70% of the antibodies could be removed from an SLE patient's plasma sample.

7. No claim is allowed.

8. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).


A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee

pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dr. Gerald Ewoldt whose telephone number is (571) 272-0843. The examiner can normally be reached Monday through Thursday from 7:30 am to 5:30 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841.

10. **Please Note:** Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). Additionally, the Technology Center receptionist can be reached at (571) 272-1600.

G.R. Ewoldt, Ph.D.  
Primary Examiner  
Technology Center 1600

  
12/15/04  
**G.R. EWOLDT, PH.D.**  
**PRIMARY EXAMINER**